151 related articles for article (PubMed ID: 23065656)
1. Phase 2 randomized study of enzastaurin (LY317615) for lung cancer prevention in former smokers.
Gray JE; Altiok S; Alexandrow MG; Walsh FW; Chen J; Schell MJ; Tai DF; Bepler G
Cancer; 2013 Mar; 119(5):1023-32. PubMed ID: 23065656
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of enzastaurin (LY317615.HCl) against human cancer cell lines and freshly explanted tumors investigated in in-vitro [corrected] soft-agar cloning experiments.
Hanauske AR; Oberschmidt O; Hanauske-Abel H; Lahn MM; Eismann U
Invest New Drugs; 2007 Jun; 25(3):205-10. PubMed ID: 17347872
[TBL] [Abstract][Full Text] [Related]
3. Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cbeta inhibitor, in non-small cell lung cancer cells.
Morgillo F; Martinelli E; Troiani T; Laus G; Pepe S; Gridelli C; Ciardiello F
Mol Cancer Ther; 2008 Jun; 7(6):1698-707. PubMed ID: 18566241
[TBL] [Abstract][Full Text] [Related]
4. The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts.
Graff JR; McNulty AM; Hanna KR; Konicek BW; Lynch RL; Bailey SN; Banks C; Capen A; Goode R; Lewis JE; Sams L; Huss KL; Campbell RM; Iversen PW; Neubauer BL; Brown TJ; Musib L; Geeganage S; Thornton D
Cancer Res; 2005 Aug; 65(16):7462-9. PubMed ID: 16103100
[TBL] [Abstract][Full Text] [Related]
5. Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines.
Rizvi MA; Ghias K; Davies KM; Ma C; Weinberg F; Munshi HG; Krett NL; Rosen ST
Mol Cancer Ther; 2006 Jul; 5(7):1783-9. PubMed ID: 16891464
[TBL] [Abstract][Full Text] [Related]
6. Protein kinase C-beta gene variants, pathway activation, and enzastaurin activity in lung cancer.
Lee SH; Chen T; Zhou J; Hofmann J; Bepler G
Clin Lung Cancer; 2010 May; 11(3):169-75. PubMed ID: 20439192
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor.
Green LJ; Marder P; Ray C; Cook CA; Jaken S; Musib LC; Herbst RS; Carducci M; Britten CD; Basche M; Eckhardt SG; Thornton D
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3408-15. PubMed ID: 16740765
[TBL] [Abstract][Full Text] [Related]
8. Lung cancer chemoprevention with celecoxib in former smokers.
Mao JT; Roth MD; Fishbein MC; Aberle DR; Zhang ZF; Rao JY; Tashkin DP; Goodglick L; Holmes EC; Cameron RB; Dubinett SM; Elashoff R; Szabo E; Elashoff D
Cancer Prev Res (Phila); 2011 Jul; 4(7):984-93. PubMed ID: 21733822
[TBL] [Abstract][Full Text] [Related]
9. A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies.
Usha L; Sill MW; Darcy KM; Benbrook DM; Hurteau JA; Michelin DP; Mannel RS; Hanjani P; De Geest K; Godwin AK
Gynecol Oncol; 2011 Jun; 121(3):455-61. PubMed ID: 21414654
[TBL] [Abstract][Full Text] [Related]
10. The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.
Wu X; Zhu M; Fletcher JA; Giobbie-Hurder A; Hodi FS
PLoS One; 2012; 7(1):e29622. PubMed ID: 22253748
[TBL] [Abstract][Full Text] [Related]
11. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.
Carducci MA; Musib L; Kies MS; Pili R; Truong M; Brahmer JR; Cole P; Sullivan R; Riddle J; Schmidt J; Enas N; Sinha V; Thornton DE; Herbst RS
J Clin Oncol; 2006 Sep; 24(25):4092-9. PubMed ID: 16943527
[TBL] [Abstract][Full Text] [Related]
12. Enzastaurin.
Chen YB; LaCasce AS
Expert Opin Investig Drugs; 2008 Jun; 17(6):939-44. PubMed ID: 18491994
[TBL] [Abstract][Full Text] [Related]
13. The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines.
Neri A; Marmiroli S; Tassone P; Lombardi L; Nobili L; Verdelli D; Civallero M; Cosenza M; Bertacchini J; Federico M; De Pol A; Deliliers GL; Sacchi S
Leuk Lymphoma; 2008 Jul; 49(7):1374-83. PubMed ID: 18452078
[TBL] [Abstract][Full Text] [Related]
14. Enzastaurin, a protein kinase Cbeta- selective inhibitor, and its potential application as an anticancer agent in lung cancer.
Herbst RS; Oh Y; Wagle A; Lahn M
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4641-6. PubMed ID: 17671157
[TBL] [Abstract][Full Text] [Related]
15. Enzastaurin (LY317615), a protein kinase C beta selective inhibitor, enhances antiangiogenic effect of radiation.
Willey CD; Xiao D; Tu T; Kim KW; Moretti L; Niermann KJ; Tawtawy MN; Quarles CC; Lu B
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1518-26. PubMed ID: 19906497
[TBL] [Abstract][Full Text] [Related]
16. Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells.
Lee KW; Kim SG; Kim HP; Kwon E; You J; Choi HJ; Park JH; Kang BC; Im SA; Kim TY; Kim WH; Bang YJ
Cancer Res; 2008 Mar; 68(6):1916-26. PubMed ID: 18339873
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of protein kinase Cbeta by enzastaurin enhances radiation cytotoxicity in pancreatic cancer.
Spalding AC; Watson R; Davis ME; Kim AC; Lawrence TS; Ben-Josef E
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6827-33. PubMed ID: 18006785
[TBL] [Abstract][Full Text] [Related]
18. Epithelial-to-mesenchymal transition and oncogenic Ras expression in resistance to the protein kinase Cbeta inhibitor enzastaurin in colon cancer cells.
Serova M; Astorgues-Xerri L; Bieche I; Albert S; Vidaud M; Benhadji KA; Emami S; Vidaud D; Hammel P; Theou-Anton N; Gespach C; Faivre S; Raymond E
Mol Cancer Ther; 2010 May; 9(5):1308-17. PubMed ID: 20406951
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II trial of sulindac for lung cancer chemoprevention.
Limburg PJ; Mandrekar SJ; Aubry MC; Ziegler KL; Zhang J; Yi JE; Henry M; Tazelaar HD; Lam S; McWilliams A; Midthun DE; Edell ES; Rickman OB; Mazzone P; Tockman M; Beamis JF; Lamb C; Simoff M; Loprinzi C; Szabo E; Jett J;
Lung Cancer; 2013 Mar; 79(3):254-61. PubMed ID: 23261228
[TBL] [Abstract][Full Text] [Related]
20. A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer.
Grønberg BH; Ciuleanu T; Fløtten Ø; Knuuttila A; Abel E; Langer SW; Krejcy K; Liepa AM; Munoz M; Hahka-Kemppinen M; Sundstrøm S
Lung Cancer; 2012 Oct; 78(1):63-9. PubMed ID: 22917813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]